Roche Enters Into A Licensing Agreement Wth Blueprint Medicines To Commercialise Cancer Drug Pralsetinib Outside The US
Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater…
Share